Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery
Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery
复制标题
DOI：
10.1046/j.1442-9071.2002.00554.x
复制
发表时间：
2002-10-01
影响因子：
4
通讯作者：
Verma, LK
中科院分区：
文献类型：
--
作者：
Kumar, A;Nainiwal, S;Verma, LK
目的：为探讨柔红霉素对视网膜脱离术后增殖性玻璃体视网膜病变的抑制作用，方法：对30例（30眼）原发性孔源性视网膜脱离合并增殖性玻璃体视网膜病变的D1期及以上患者进行了研究。眼睛被随机分配到实验组或对照组。实验组的眼睛在玻璃体切除术结束前接受玻璃体内注射柔红霉素（5 μ g）。主要的结果评估措施是：视网膜附着，玻璃体活动和视力在3个月后survey.Results：在柔红霉素组和对照组中，在3个月时，在13只眼睛（86.6%）和10只眼睛（66.6%）的视网膜完全附着。柔红霉素组9例患者（60%）和对照组5例患者（33.3%）在3个月随访时最佳矫正视力大于或等于3/60。有一个统计学上显着减少玻璃体反应在所有时间在术后期间的柔红霉素group.Conclusion：柔红霉素可能是一种有用的药物，在抑制增殖性玻璃体视网膜病变手术后原发性孔源性视网膜脱离。
Purpose : To study the role of daunorubicin in inhibiting pro-liferative vitreoretinopathy after retinal detachment surgery.Method: Thirty eyes of 30 patients with a primary rhegmato-genous retinal detachment and proliferative vitreoretin-opathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of dauno-rubicin (5 mug) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best-corrected visual acuity of greater than or equal to3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.